Paras Healthcare IPO Details: Key Dates, Price Band & Investment Overview

By Wealthova | Last Updated: October 21, 2026

Paras Healthcare Limited, operating under the well-established brand Paras Health, is gearing up to make a significant primary market debut with an upcoming ₹1,450.00 Crore mainboard IPO. Operating as a premier multi-specialty healthcare services provider, the company manages an expansive network of eight hospitals equipped with a robust 2,211-bed capacity across North India, Bihar, and Jharkhand. Empowered by a highly experienced workforce of over 1,000 doctors and a strategic focus on high-acuity CONGOR (Cardiac, Oncology, Neuro, Gastro, Ortho, and Renal) specialties, the company serves as a critical healthcare pillar in underserved regions. The subscription window for this highly anticipated book-built issue opens on October 21, 2026, and closes on October 23, 2026. The price band is set between ₹660 to ₹693 per equity share. The ₹1,450.00 Crore offering is structured as a combination of a ₹500.00 Crore Fresh Issue and an Offer for Sale (OFS) of ₹950.00 Crore by existing promoters and investors. Retail investors must apply for a minimum of 1 lot (21 shares), requiring an accessible investment of ₹14,553 at the upper price band. With the ₹500 Crore Fresh Issue component, the company will strategically utilize ₹320.90 Crore to rapidly prepay and repay outstanding corporate borrowings, while allocating additional funds to deleverage its subsidiary, PMHPL. Set to list on both the BSE and NSE platforms, market participants are closely watching this fast-growing hospital chain, which reported a robust FY26 Total Income of ₹1,628.78 Crore alongside surging profitability and EBITDA margins. Below, we break down the financial health, industry risk factors, and our honest Smart Market Insights to help you decide if you should subscribe to this issue!

Paras Healthcare Limited, operating under the well-established brand Paras Health, is a prominent clinical specialty-led hospital platform delivering tertiary and quaternary care across North India. The company operates a robust network of eight multi-specialty hospitals with a total capacity of 2,211 beds across five states, establishing a formidable first-mover advantage in high-growth, under-penetrated Tier-2 healthcare markets such as Patna, Darbhanga, Ranchi, and Srinagar.

Supported by a highly skilled medical workforce of over 1,084 doctors and 1,937 nurses, the company's core operations are defined by:

• High-Acuity CONGOR Focus: Paras Health specializes in complex, high-acuity medical treatments across Cardiac, Oncology, Neuro, Gastro, Orthopaedics, and Renal sciences. These critical, high-margin specialty segments are the engine of the business, contributing an impressive 74.70% of its total FY26 operating revenue.
• Capital-Efficient Expansion: By leveraging a strategic, calibrated mix of owned and leased hospital facilities, the company maintains a highly efficient capital expenditure model, operating at a development cost of just ₹77 Lakh per bed.
• Aggressive Growth Pipeline: Driven by surging patient volume and high occupancy rates (approaching 70%), the company is actively executing a massive capacity expansion plan. With a 300-bed facility upcoming in Gurugram (FY27) and a 500-bed hospital planned for Ludhiana (FY28), Paras Health is targeting 3,011 operational beds by March 2028.

The ₹1,450.00 Crore Paras Healthcare IPO is a combined offering comprising a ₹500.00 Crore Fresh Issue and a ₹950.00 Crore Offer for Sale (OFS). While the ₹950 Crore OFS proceeds will go directly to the selling promoters and early institutional investors to provide a structured liquidity exit, the company itself will receive the entire ₹500 Crore from the Fresh Issue.

These fresh funds will be strategically deployed to fortify the balance sheet through the following primary objectives:

• Direct Corporate Debt Repayment (₹320.90 Crore): The absolute priority is aggressive deleveraging. The company will utilize the majority of the fresh funds for the full or partial prepayment and scheduled repayment of its outstanding corporate borrowings, dramatically reducing its annual interest burden.
• Subsidiary Debt Repayment (₹54.10 Crore): An additional tranche will be invested directly into its wholly-owned subsidiary, PMHPL (which operates the prominent Srinagar hospital facility), specifically to prepay or repay its outstanding debt. Combined, this ₹375.00 Crore debt reduction will significantly expand the company's net profitability margins post-listing.
• General Corporate Purposes (₹125.00 Crore): The remaining balance will be retained to fund ongoing hospital operations, support new capacity commercialization, and cover standard issue-related expenses.